240 likes | 441 Views
Post Herpetic Neuralgia. Stephen May. Introduction. "O’er ladies’ lips, who straight on kisses dream;Which oft the angry Mab with blisters plagues." Romeo and Juliet (W. Shakespeare).
E N D
Post Herpetic Neuralgia Stephen May
Introduction • "O’er ladies’ lips, who straight on kisses dream;Whichoft the angry Mab with blisters plagues." • Romeo and Juliet (W. Shakespeare). • "Whether or not the unknown infectious material of chickenpoxcould under certain circumstances manifest itself instead asa zoster eruption." • James von Bokay 1892.
Introduction • Smallpox and chickenpox different • 1904 Ernest Tyzzer • Zoster fluid could infect with varicella • 1925 Kundratitz • Weller et al in 1958 : same virus responsible for both • Hope-Simpson : zoster is due to varicella virus reactivation
Introduction • PHN is one of the most painful neuropathic conditions • Usually VZV reactivation • PHN : 1-6 mth post acute HZ • Risk increases with age • Usually a single unilateral dermatome • Thoracic and V1 most common
Pathophysiology • Acute infection : necrotising reaction in dorsal horn • Large myelinated fibres are most extensively damaged • Increased transfer at dorsal horn from smaller fibres (nociceptive info) • Reduced innervation noted at affected skin • Changes evident in CNS
Pathophysiology • PHN – 2 types of pain • Steady, aching, boring pain • Paroxysmal lancing pain • Allodynia, hyperalgesia, hyperaesthesia often occur • Explained by 2 different mechanisms
Pathophysiology • Sensitisation • Acute injury -> ongoing discharge and hyperexcitability of nociceptor (peripheral sensitisation) • Prolonged nociceptor discharge -> enhanced dorsal horn response to afferent neurones with expansion of receptive field (central sensitisation) • Explains allodynia without marked sensory loss
Pathophysiology • Deafferentation • VZV reactivation in DRG ->inflammation -> neural damage and oedema • Reduced endoneurial blood flow (↑P) • Neural destruction • Loss of afferent neurones -> spontaneous activity in deafferenated central neurones • Constant pain in area of sensory loss and minimal allodynia
Pathophysiology Reactive sprouting of spinal terminals of AB mechanoreceptors to receptors formerly occupied by C-fibres results in hyperalgesia and allodynia
Pathophysiology 3 subtypes • Irritable nociceptor subtype Damaged primary afferent nociceptors responsible for allodynia Little deficit in sensory thresholds as sensory signalling still occurs
Pathophysiology 2) Deafferenated allodynic subtype Primary afferents more extensively damaged C fibres develop neuromata (spont discharge) -> dorsal horn sensitisation Selective loss of C fibres (touch preserved) Surviving AB fibres discharge normally -> light touch signalling pain
Pathophysiology 2) Deafferenated non-allodynic subtype V. Extensive nerve damage Skin insensitive to all modalities Pain as a consequence of central sensitisation and neuronal reorganisation
Management : Prevention • Increasing evidence for vaccination • Acts to increase cell mediated immunity • 2006 : UFDA have approved use • Amitriptyline has been suggested as prophylactic drug
Management : Acute HZ • Antivirals • Corticosteroids • Standard analgesia • ? Epidural LA + steroid beneficial for pain • Possibly only short term effect and no clear evidence in reducing PHN incidence
Management : PHN • Mainstay of treatment is • Anticonvulsants • Antidepressants • Opiates • Increasing evidence for lidocaine patches as first line therapy
Management : PHN • TCA’s : NNT 2.3 for 50% pain relief • 30% minor SE’s, 4% more severe SE • NNH 22 (major), 3.7 (minor) • SSRI better tolerated but less effective • GONIP trial (nortriptyline v gabapentin) : similar effects on pain and sleep, gabapentin better tolerated
Management : PHN • Only 2/3 taking carbamazepine or gabapentin for neuropathic pain get benefit • ? Best for lancinating or burning pain • NNT 3.9, RR 2.5 • Pregabalin may be tried where gabapentin not tolerated • ? Lamotrigine – not licensed for PHN in Europe
Management : PHN • Lidocaine patch 5% • Reasonable first line choice and cost effective • NO SIGNIFICANT SYSTEMIC SE’S • Can get mild skin reaction • Shown to have central effects
Management : PHN • Opiates – partially effective, not 1st line • Capsaicin –NNT 5.3 for 0.075% • Will increase pain in irritable nociceptor subgroup – contraindicated • TENS – to be effective : need sufficient innervation from normally conducting fast fibres
Management : PHN • Epidural LA + Steroid • Evidence of effects on reducing pain • General consensus is of little effect on PHN development • ? Intrathecal methyprednisolone • Occasional small scale evidence for peripheral or sympathetic blocks – no RCT
Management : Miscellaneous • Prostaglandin E2 • UVB in acute HZ • ? Myofascial component in resistant cases • LA + steroid local infiltration • Botulinum toxin A • Local skin excision (irritable nociceptor subgroup) • Intrathecal baclofen • Iv ATP
References • 1)Bandolier. http://www.jr2.ox.ac.uk/bandolier/index.html • 2)Gabapentin for acute and chronic pain, Cochrane review 2005 • 3)Anticonvulsant drugs for acute and chronic pain, Cochrane review 2007 • 4)Kanari et al. Effectiveness of Prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. Pain Med. 2007 Jan-Feb; 8(1): 36-40 • 5)Smith and Roberts. Sequential Medication Strategies for Post Herpetic Neuralgia : A Cost-Effectiveness Analysis. Pain 2007 Jan 19 • 6)Opstelten et al. Treatment of patients with herpes zoster by epidural injection of steroids and local anaesthetics : less pain after one month but no effect on long-term post herpetic neuralgia – a randomized trial. Ned Tijdschr Geneeskd 2006. Dec 2; 150(48) : 2649-55 • 7)Sederholm and Patterson. Zoster vaccine to prevent post herpetic neuralgia. J. Pain Palliat Care Pharmacother 2006; 20(4) : 41-2 • 8)Rotty et al. Interleukin 2 – A potential treatment option for post herpetic neuralgia. Clin Infect Dis 2006 Dec15; 43(12) : e109-10 • 9)Chen et al. Treatment of postherpetic neuralgia with intravenous administration of vitaminC.Anesth Analg.2006; 103: 1616-1617 • 10)Key Topics in Chronic Pain. Bios. Grady,Severn, Eldridge • 11)Geha et al. Brain activity for spontaneous pain of post herpetic • neuralgia and its modulation by lidocaine patch therapy. Pain 2006 • Oct 24 Article in press (corrected proof viewed online) • 12)Vister and Kwai. Salmon Calcitonin in the treatment of post • herpetic neuralgia. Anaesth Intensive Care. 2006 Oct; 34(5) : 668- • 71 • 13) Holcomb and Weinberg. A novel vaccine (zostavax) to prevent • herpes zoster and postherpetic neuralgia. J Drugs Dermatol. 2006 • Oct; 5(9): 863-6
References • 14)Holodnig. Prevention of shingles by varicella zoster virus • vaccination. Expert Rev Vaccines. 2006 Aug: 5(4) : 431-43 • 15)Chandra et al. Gabapentin versus nortriptyline in post herpetic • neuralgia patients : a randomized, double-blind clinical trial – The • GONIP Trial. Int J Clin Pharmacol Ther. 2006 Aug: 44(8): 358-63 • 16)Jalali et al. Broad band ultraviolet B phototherapy in zoster patients • may reduce the incidence and severity of post herpetic neuralgia. • Photodermatol Photoimmunal Photomed. 2006 Oct;22(5) 232-7 • 17)Niv and Maltsman-Tseikhin. Post Herpetic Neuralgia : the never- • ending challenge. Pain Pract 2005 Dec; 5(4): 327-40 • 18)Humpenstall et al. Analgesic Therapy in Postherpetic Neuralgia : • A Quantitative Systematic Review. PLOS Med 2005 Jul; 2(7)e164 • 19)Weiner and Schmader. Post Herpetic Pain: More Then Sensory • Neuralgia? Pain Med 2006 May-Jun: 7(3) 243-9 • 20)Stolker et al. The PINE study of epidural steroids and local • anaesthetics to prevent postherpetic neuralgia : a randomized • controlled trial. Lancet 2006 Jan 21; 367(9506): 219-24 • 21)Amjad and Mashhood. The efficacy of local infiltration of • triamcinolone acetonide with lignocaine compared with lignocaine • alone in the treatment of postherpetic neuralgia. J Coll Physician • Surg Pak. 2005 Nov; 15(11): 683-5 • 22)Oxman et al. A vaccine to prevent herpes zoster and post herpetic • neuralgia in older adults. N Engl J Med 2005 Jun 2; 352(22): 2271- • 84 • 23)Hardy. Relief of pain in acute herpes zoster by nerve blocks and • possible prevention of post herpetic neuralgia. Canadian Journal of • Anesthesia52:186-190 (2005)
References • 24)Hagashida et al. Analgesic effect of intravenous ATP on • postherpetic neuralgia in comparison with responses to intravenous • ketamine and lidocaine. J Anaesth 2005 ; 19(1): 31-5 • 25)Kumar et al. Neuraxial and sympathetic blocks in herpes zoster • and post herpetic neuralgia : an appraisal of current evisence. Reg • Anaesth Pain Med 2004 Sep-Oct; 29(5): 454-61 • 26)Davies and Galer. Review of lidocaine patch 5% studies in the • treatment of postherpetic neuralgia. Drugs 2004; 64(9): 937-47 • 27)Hsu-Tang et al. Botulinum toxin. A relieved neuropathic pain in a • case of post herpetic neuralgia. Pain Medicine Vol 6. No 1, 89-91 • 28)Peterson et al. Relief of Post Herpetic Neuralgia by Surgical • Removal of Painful Skin. Pain 98(1-2):119-26, 2002 Jul • 29)Hosny et al. Response of intractable post herpetic neuralgia to • intrathecal baclofen. Pain Physician : 2004;7:345-347 • 30)Johnson and Dwarkin. Clinical Review. Treatment of Herpes • Zoster and Postherpetic Neuralgia. BMJ: 2003;32(6):748-50 • 31)Hayashida et al. Analgesic effect of intravenous ATP on post • herpetic neuralgia in comparison to responses to intravenous • ketamine and lidocaine. J. Anaesth 2005; 19(1): 31-5